<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2604-1227</journal-id>
<journal-title><![CDATA[Revista mexicana de oftalmología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. oftalmol]]></abbrev-journal-title>
<issn>2604-1227</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oftalmología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2604-12272019000500238</article-id>
<article-id pub-id-type="doi">10.24875/rmo.m19000085</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Resultados del tratamiento a doce meses con ranibizumab para el edema macular diabético en la práctica clínica de rutina en México]]></article-title>
<article-title xml:lang="en"><![CDATA[Twelve-month outcomes of ranibizumab for diabetic macular edema in routine clinical practice in Mexico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Orozco-Gómez]]></surname>
<given-names><![CDATA[Luis P.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Salazar]]></surname>
<given-names><![CDATA[Leonor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Peredo]]></surname>
<given-names><![CDATA[Vanesa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortega-Villalobos]]></surname>
<given-names><![CDATA[Alma L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aranda-Serna]]></surname>
<given-names><![CDATA[Sergio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gerardo-Ferreyra]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-González]]></surname>
<given-names><![CDATA[Elisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Monjaraz]]></surname>
<given-names><![CDATA[Julio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-Franco]]></surname>
<given-names><![CDATA[Alejandra Sabina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Centro Médico Nacional 20 de Noviembre ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Lic. Adolfo López Mateos ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital 1º de Octubre ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Regional Gral. Ignacio Zaragoza ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>93</volume>
<numero>5</numero>
<fpage>238</fpage>
<lpage>245</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2604-12272019000500238&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2604-12272019000500238&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2604-12272019000500238&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Evaluar los resultados de agudeza visual (AV) y grosor retiniano central (GRC) en pacientes con edema macular diabético (EMD) tratados con ranibizumab en la práctica clínica de rutina en México.  Métodos: Se realizó un estudio prospectivo, abierto y de un solo grupo en 48 ojos de 34 pacientes con EMD con involucro central, en cuatro hospitales de alta especialidad del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSTE). Los pacientes iniciaron con una dosis de carga de 3 inyecciones de ranibizumab 0.5 mg, seguido de monitoreo mensual con base en la AV y el GRC, para determinar la necesidad de retratamiento. La AV, el GRC, el puntaje en la Escala de severidad de la retinopatía diabética (DRSS) del ETDRS y el número de inyecciones se registraron al inicio y de manera mensual hasta los 12 meses.  Resultados: La AV promedio, el GRC promedio y el puntaje promedio de la DRSS basales fueron 19 (±14) letras ETDRS, 362 (±98) µm y 50.59 (±7.9), respectivamente. El cambio promedio en AV a los 12 meses fue de +8.6 (±4.3) letras (p &lt; 0.001) respecto a la situación basal. El 39.58% de los ojos (n = 19) ganó &#8805; 10 letras y el 37.50% (n = 18) ganó &lt; 10 letras. El 4.16% (n = 2) se mantuvo estable y el 18.75% (n = 9) perdió &lt; 10 letras. A los 12 meses, el cambio promedio en el GRC fue de &#8722;85.34 (±32.1) µm (p &lt; 0.001). El puntaje promedio de la DRSS fue de 45.79 (±7.9) en el mes 12 (p &lt; 0.001). Una media de 6.7 (±2.2) inyecciones fue aplicada durante 12 meses.  Conclusión: Los pacientes mostraron mejoría visual y anatómica después de recibir ranibizumab en la práctica clínica en México.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Purpose: To evaluate visual acuity (VA) and central retinal thickness (CRT) outcomes in patients treated with ranibizumab for diabetic macular edema (DME) in a clinical setting in Mexico.  Methods: A prospective, open-label, single arm study was performed on 48 eyes of 34 patients with center-involving DME at four high-specialty ISSSTE hospitals in Mexico. Patients initially received a loading dose of 3 injections of ranibizumab, followed by monthly monitoring based on VA and CRT to determine retreatment need. VA, CRT, ETDRS diabetic retinopathy severity scale (DRSS) score, and number of injections were recorded at baseline and monthly for 12 months.  Results: The mean VA, mean CRT, mean DRSS score at baseline were 19 (± 14) ETDRS letters, 362 (± 98) µm and 50.59 (± 7.9). The mean VA change at 12 months was +8.6 (± 4.3) letters (p &lt; 0.001) from baseline. The proportion of eyes that gained &#8805; 10 letters was 38.58% (n = 19) and 37.50% (n = 18) gained &lt; 10 letters; 4.16% (n = 2) had no change, and 18.75% (n = 9) lost &lt; 10 letters. At month 12, mean CRT change was &#8722;85.34 (± 32.1) µm (p &lt; 0,001) and the DRSS score was 45.79 (± 7.9) (p &lt; 0.001). Patients received a mean of 6.7 (± 2.2) injections over 12 months.  Conclusion: Patients showed visual and anatomical improvement after receiving ranibizumab in a clinical setting in Mexico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Edema macular diabético]]></kwd>
<kwd lng="es"><![CDATA[Ranibizumab]]></kwd>
<kwd lng="es"><![CDATA[Anti-VEGF]]></kwd>
<kwd lng="es"><![CDATA[Retinopatía diabética]]></kwd>
<kwd lng="es"><![CDATA[Inyección intravítrea]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[Diabetic macular edema]]></kwd>
<kwd lng="en"><![CDATA[Ranibizumab]]></kwd>
<kwd lng="en"><![CDATA[Anti-vascular endothelial growth factor]]></kwd>
<kwd lng="en"><![CDATA[Diabetic retinopathy]]></kwd>
<kwd lng="en"><![CDATA[Intravitreal injection]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>International Diabetes Federation</collab>
<source><![CDATA[IDF Diabetes Atlas]]></source>
<year>2015</year>
<edition>7th ed</edition>
<publisher-loc><![CDATA[Brussels, Belgium ]]></publisher-loc>
<publisher-name><![CDATA[IDF Executive Office]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez-Avila]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierrez]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes mellitus:la urgencia de reforzar la respuesta en políticas públicas para su prevención y control]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Mexico ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prado-Serrano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guido-Jimenez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Camas-Benitez]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de retinopati?a diabe?tica en poblacio?n mexicana]]></article-title>
<source><![CDATA[Rev Mex Oftalmol]]></source>
<year>2009</year>
<volume>83</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>261-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[DeMets]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>1984</year>
<volume>91</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1464-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Hopkins]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sorof]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrlich]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-vascular endothelial growth factor therapy for diabetic macular edema]]></article-title>
<source><![CDATA[Ther Adv Endocrinol Metab]]></source>
<year>2013</year>
<volume>4</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>151-69</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Massin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bandello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Garweg]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Harding]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study):a 12-month, randomized, controlled, double-masked, multicenter phase II study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2010</year>
<volume>33</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2399-405</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Massin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bressler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Coon]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Petrillo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab:the RESTORE extension study]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2015</year>
<volume>31</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1967-75</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prünte]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fajnkuchen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmood]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ricci]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hatz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Studni&#269;ka]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ranibizumab 0.5?mg treat-and-extend regimen for diabetic macular oedema:the RETAIN study]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2016</year>
<volume>100</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>787-95</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Dal Pan]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Gerry]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[Gross]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world evidence - what is it and what can it tell us?]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>2293-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertelmann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Feltgen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Scheffler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hufenbach]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Wiedon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wilhelm]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice:baseline data from the German OCEAN study]]></article-title>
<source><![CDATA[Health Qual Life Outcomes]]></source>
<year>2016</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>132</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghanchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hazel]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience]]></article-title>
<source><![CDATA[Eye Lond Engl]]></source>
<year>2016</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>133-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granström]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Forsman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lindholm]]></surname>
<given-names><![CDATA[Olinder A]]></given-names>
</name>
<name>
<surname><![CDATA[Gkretsis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Granstam]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2016</year>
<volume>121</volume>
<page-range>157-65</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Salazar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aranda-Serna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Orozco-Gómez]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Azuara-Azuara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bracamontes-Barragán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Collado-Solórzano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía para el diagnóstico y el tratamiento del edema macular diabético en derechohabientes del ISSSTE]]></article-title>
<source><![CDATA[Rev Esp Med Quir]]></source>
<year>2015</year>
<volume>20</volume>
<page-range>321-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osaadon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fagan]]></surname>
<given-names><![CDATA[XJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lifshitz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of anti-VEGF agents for proliferative diabetic retinopathy]]></article-title>
<source><![CDATA[Eye (Lond)]]></source>
<year>2014</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>510-20</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ip]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrlich]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical importance of changes in diabetic retinopathy severity score]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2017</year>
<volume>124</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>596-603</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathur]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bhaskaran]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chaturvedi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Smeeth]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[population trends in the Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK:a cohort study in the Clinical Practice Research Datalink 2004–2014]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2017</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dugel]]></surname>
<given-names><![CDATA[PU]]></given-names>
</name>
<name>
<surname><![CDATA[Hillenkamp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sivaprasad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vögeler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mousseau]]></surname>
<given-names><![CDATA[M-C]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials]]></article-title>
<source><![CDATA[Clin Ophthalmol Auckl NZ]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>1103-10</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
